Proteomics International Laboratories has secured a United States patent for PromarkerEndo, its proprietary blood test for diagnosing endometriosis, a development the company describes as a major step toward global commercialisation.

Seventeen of Australia’s leading medical and science organisations have come together to warn the Albanese Government that proposed changes to the Research and Development Tax Incentive risk hollowing out the country’s life sciences and medical technology sectors.

Australia’s largest life sciences private equity company, Brandon Capital, has announced a landmark exit as Novartis moves to acquire its portfolio company Myricx Bio in a deal valued at up to US$1.5 billion, including an upfront cash payment of US$1.1 billion and further milestone payments. 

The company said the funds raised will go towards the development of its lead allogeneic CAR T therapy, azer-cel, into calendar year 2027, including clinical and regulatory activities, manufacturing scale-up and general working capital.

Australian company Syntara and Parkinson’s Research Ventures have reported early signs that a novel anti-inflammatory candidate may reduce brain inflammation in people at high risk of developing Parkinson’s disease.

CEO and Managing Director Dr David Foster said, "Securing all regulatory and ethics approvals to commence this effort represents a significant milestone for galidesivir and the culmination of more than a year of collaboration with our partners in Uganda and the ACCEPT Africa Consortium."

Cartherics has been recognised as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell and Gene Therapy Excellence Awards 2026, a milestone that highlights the company's rise in the off-the-shelf immune cell therapy field.

BCAL said the investment is a way to add an infectious disease diagnostics pillar to its existing early cancer detection business, linking Genetic Signatures EasyScreen PCR products and 3base technology with BCAL’s oncology liquid biopsy and breast cancer test offerings.

Thirty Australian women have already experienced restorative breast surgery using absorbable scaffolds designed to regenerate lost breast tissue, and the company behind the technology is moving quickly through human trials.

AdAlta has announced a strategic collaboration with Oktopi to access its software-as-a-service knowledge system, designed to sharpen decisions in medicine development.

OncoSil Medical has been chosen to join PALACROS, a major European academic consortium aimed at improving outcomes for patients with unresectable locally advanced pancreatic cancer.

Starpharma has reported encouraging preclinical results for its DEP HER2-targeted radiotherapy candidate, DEP HER2 Lu, paving the way for a planned first-in-human Phase 1 study in the second half of 2026.

Neuren CEO Jon Pilcher said, “I am so delighted for all stakeholders to see this positive outcome from the CHMP re-examination process recommending marketing authorisation for DAYBU in the EU."

Chief Executive Officer James Graham said, "The capital raising comes at an exciting time for the Recce business, having recently signed a non-binding term sheet with a leading Middle Eastern Pharmaceuticals Company, and ahead of interim data readouts in Indonesia, which is a positive step towards the potential commercialisation of R327G."

The company said the funds will underwrite ongoing investment in the development and commercialisation of its blood-based early cancer detection portfolio and support planned activities through 2027.

Dr Bill Mezzanotte, CSL’s Head of Research and Development, said, “While we are disappointed in the outcome of the Article 20 procedure, we will respect the regulatory process and are committed to implementing it in full."

Algorae Pharmaceuticals has been announced as a founding participant and the healthcare and life sciences launch partner for the Sovereign AI Infrastructure initiative, led by AgenticScale.ai and built on NVIDIA-accelerated technology.